Ascelia Pharma Management
Management criteria checks 3/4
Ascelia Pharma's CEO is Magnus Corfitzen, appointed in Jan 2014, has a tenure of 12.5 years. total yearly compensation is SEK4.89M, comprised of 47.1% salary and 52.9% bonuses, including company stock and options. directly owns 0.6% of the company’s shares, worth SEK417.07K. The average tenure of the management team and the board of directors is 3.8 years and 9.5 years respectively.
Key information
Magnus Corfitzen
Chief executive officer
SEK 4.9m
Total compensation
| CEO salary percentage | 47.10% |
| CEO tenure | 12.5yrs |
| CEO ownership | 0.6% |
| Management average tenure | 3.8yrs |
| Board average tenure | 9.5yrs |
Recent management updates
Recent updates
ACE: FDA Type A Meeting Will Drive Reassessment Of Long-Term Upside
Analysts have cut their Ascelia Pharma price target to SEK 3.70 from SEK 8.50, citing updated assumptions around revenue growth, profit margins and a lower future P/E multiple that together point to a more cautious valuation framework. What’s in the News for Ascelia Pharma Ascelia Pharma received a Complete Response Letter (CRL) from the U.S. FDA on its New Drug Application for Orviglance, with the agency requesting additional clinical data and product documentation.
ACE: Rising Long-Term Prospects Will Outweigh Present Going Concern Risk
Analysts have revised their price target on Ascelia Pharma to SEK4.28 from SEK6.32, reflecting updated assumptions on the discount rate, revenue growth outlook, profit margin expectations, and future P/E multiples. What's in the News for Ascelia Pharma Ascelia Pharma scheduled an Analyst and Investor Day, described as "Ascelia Pharma AB (publ) Analyst/Investor Day," giving the market a dedicated forum to hear directly from management and review the company story.Renal Imaging Opportunity Will Support Future Rare Oncology Expansion Narrative
Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes drugs in rare oncology, with a focus on liver imaging and oral chemotherapy. What are the underlying business or industry changes driving this perspective?
Severe Regulatory And Funding Risks Around Cancer Imaging Will Eventually Reward Patient Safety Focus
Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes specialty drugs for rare cancer related conditions, focused on diagnostic imaging and oral oncology treatments. What are the underlying business or industry changes driving this perspective?Manganese Contrast Agent Safety Tailwinds Will Support Long Term Upside Potential
Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes specialty drugs for rare, cancer related conditions. What are the underlying business or industry changes driving this perspective?We're Hopeful That Ascelia Pharma (STO:ACE) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is Ascelia Pharma (STO:ACE) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is Ascelia Pharma (STO:ACE) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like
The big shareholder groups in Ascelia Pharma AB (publ) ( STO:ACE ) have power over the company. Large companies usually...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -SEK 71m |
| Dec 31 2025 | SEK 5m | SEK 2m | -SEK 76m |
| Sep 30 2025 | n/a | n/a | -SEK 89m |
| Jun 30 2025 | n/a | n/a | -SEK 95m |
| Mar 31 2025 | n/a | n/a | -SEK 85m |
| Dec 31 2024 | SEK 5m | SEK 2m | -SEK 80m |
| Sep 30 2024 | n/a | n/a | -SEK 62m |
| Jun 30 2024 | n/a | n/a | -SEK 62m |
| Mar 31 2024 | n/a | n/a | -SEK 89m |
| Dec 31 2023 | SEK 4m | SEK 2m | -SEK 109m |
| Sep 30 2023 | n/a | n/a | -SEK 152m |
| Jun 30 2023 | n/a | n/a | -SEK 157m |
| Mar 31 2023 | n/a | n/a | -SEK 139m |
| Dec 31 2022 | SEK 5m | SEK 2m | -SEK 131m |
| Sep 30 2022 | n/a | n/a | -SEK 113m |
| Jun 30 2022 | n/a | n/a | -SEK 115m |
| Mar 31 2022 | n/a | n/a | -SEK 126m |
| Dec 31 2021 | SEK 15m | SEK 2m | -SEK 126m |
| Sep 30 2021 | n/a | n/a | -SEK 127m |
| Jun 30 2021 | n/a | n/a | -SEK 113m |
| Mar 31 2021 | n/a | n/a | -SEK 111m |
| Dec 31 2020 | SEK 5m | SEK 2m | -SEK 99m |
| Sep 30 2020 | n/a | n/a | -SEK 90m |
| Jun 30 2020 | n/a | n/a | -SEK 88m |
| Mar 31 2020 | n/a | n/a | -SEK 71m |
| Dec 31 2019 | SEK 3m | SEK 992k | -SEK 66m |
Compensation vs Market: Magnus's total compensation ($USD502.94K) is above average for companies of similar size in the Swedish market ($USD383.44K).
Compensation vs Earnings: Magnus's compensation has been consistent with company performance over the past year.
CEO
Magnus Corfitzen (51 yo)
Mr. Magnus O. Corfitzen serves as the Chief Executive Officer at Ascelia Pharma AB since 2014. He serves as a Director of NsGene A/S. He serves as a Director of DentoFit A/S.Mr. Corfitzen serves on the bo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 12.5yrs | SEK 4.89m | 0.60% SEK 417.1k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Operating Officer | less than a year | no data | 0.058% SEK 40.2k | |
| Chief Scientific Officer | 3.8yrs | no data | 0.10% SEK 71.4k | |
| Head of IR & Communications | 8.5yrs | no data | no data |
Experienced Management: ACE's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman of the Board of Directors | 9.5yrs | SEK 566.00k | 0.13% SEK 91.9k | |
| Independent Director | 9.5yrs | SEK 263.00k | 0.015% SEK 10.3k | |
| Independent Director | 6.2yrs | SEK 263.00k | no data | |
| Independent Director | 9.5yrs | SEK 363.00k | 0.082% SEK 56.3k | |
| Independent Director | 1.8yrs | SEK 304.00k | no data |
Experienced Board: ACE's board of directors are considered experienced (9.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/27 10:58 |
| End of Day Share Price | 2026/07/27 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ascelia Pharma AB (publ) is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier Sponsored |
| Lars Hevreng | Danske Bank |
| Maria Karlsson Osipova | DNB Carnegie Commissioned Research |